Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5670a/b booster versus Comirnaty in children aged 5 to 11 years
jRCT2031220665Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing DS-5670a/b booster with Comirnaty booster (2 arms). Primary endpoints: Geometric mean titer of neutralizing antibodies against SARS-CoV-2 Omicron BA.5 and Seroresponse rate against SARS-CoV-2 Omicron BA.5. Started May 2023; status: completed.
02
Drugs
DS-5670a + DS-5670btozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220665.